The concepts and clinical practices of blocking the interactions between tumor surface programmed cell death ligand-1 (PD-L1) and the programmed cell death protein 1 (PD-1) on the surface of effector T cells have revolutionized cancer immunotherapies. The gene discussed is PDCD1; the disease is cancer.